Back to results
US 2026/0256905 A1Published application
Broad-spectrum multi-antigen pan-coronavirus vaccine
AssigneeThe Regents of the University of California
InventorLbachir BenMohamed
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe Regents of the University of California
InventorLbachir BenMohamed
Estimating the term…
Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.
-24. (canceled)
A composition, comprising a lipid nanoparticle, wherein the lipid nanoparticle comprises a first messenger ribonucleic acid (mRNA) encapsulated therein, a second mRNA encapsulated therein, and a third mRNA encapsulated therein, wherein:
A composition, comprising a lipid nanoparticle, wherein the lipid nanoparticle comprises a first messenger ribonucleic acid (mRNA) encapsulated therein, a second mRNA encapsulated therein, and a third mRNA encapsulated therein, wherein:
Dependencies are inferred from the claim text.